Literature DB >> 2619225

Early diagnosis in colorectal cancer still no benefit?

R Ratcliffe, R S Kiff, E M Hoare, R D Kingston, S H Walsh, J Jeacock.   

Abstract

Delay to diagnosis from first symptom has been assessed in 332 patients with colorectal cancer treated by the three general surgeons in Trafford Health Authority. Delay was divided into three parts; that due to (a) the patient, (b) the general practitioner and (c) the hospital. There was no significant difference in delay between Dukes stage B and C patients but there was a significant difference in survival at two years between these two stages. Delay for patients with risk factors as family histories or diverticular disease was not significantly different to patients without these factors. When compared to other series delay has been shortened, particularly general practitioner and hospital delay. Fewer patients presented as emergencies and a greater proportion of patients had disease at an earlier stage. However, these favourable aspects are not reflected in an improved survival at 2 years.

Entities:  

Mesh:

Year:  1989        PMID: 2619225

Source DB:  PubMed          Journal:  Ann Chir        ISSN: 0003-3944


  3 in total

1.  Blood-Cell-Based Inflammatory Markers as a Useful Tool for Early Diagnosis in Colorectal Cancer.

Authors:  Maria Hernandez-Ainsa; Raul Velamazan; Angel Lanas; Patricia Carrera-Lasfuentes; Elena Piazuelo
Journal:  Front Med (Lausanne)       Date:  2022-06-20

2.  Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study.

Authors:  Jochim S Terhaar sive Droste; Frank A Oort; René W M van der Hulst; Veerle M H Coupé; Mike E Craanen; Gerrit A Meijer; Linde M Morsink; Otto Visser; Roy L J van Wanrooij; Chris J J Mulder
Journal:  BMC Cancer       Date:  2010-06-28       Impact factor: 4.430

3.  Factors related with symptom duration until diagnosis and treatment of symptomatic colorectal cancer.

Authors:  Magdalena Esteva; Alfonso Leiva; María Ramos; Salvador Pita-Fernández; Luis González-Luján; Montse Casamitjana; María A Sánchez; Sonia Pértega-Díaz; Amador Ruiz; Paloma Gonzalez-Santamaría; María Martín-Rabadán; Ana M Costa-Alcaraz; Alejandro Espí; Francesc Macià; Josep M Segura; Sergio Lafita; Francisco Arnal-Monreal; Isabel Amengual; Marta M Boscá-Watts; Angels Hospital; Hermini Manzano; Rosa Magallón
Journal:  BMC Cancer       Date:  2013-02-23       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.